Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2015-004917-26
    Sponsor's Protocol Code Number:PS-G202
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Completed
    Date on which this record was first entered in the EudraCT database:2020-11-04
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2015-004917-26
    A.3Full title of the trial
    A Phase 2a, 2-part, Randomized, Double-blind, Placebo-controlled, Incomplete Block Crossover Study to Evaluate the Safety and Efficacy of VX-371 Solution for Inhalation With and Without Oral Ivacaftor in Subjects With Primary Ciliary Dyskinesia
    Studio di Fase 2a, in 2 parti, randomizzato, in doppio cieco, controllato da placebo, in crossover a blocchi incompleti per la valutazione di sicurezza ed efficacia della soluzione VX-371 per inalazione con e senza ivacaftor per via orale in soggetti affetti da discinesia ciliare primaria
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    CLEAN-PCD: Clearing Lungs with ENaC Inhibition in Primary Ciliary Dyskinesia
    CLEAN-PCD: pulizia dei polmoni con l¿inibizione dell¿ENaC nella discinesia ciliare primaria
    A.3.2Name or abbreviated title of the trial where available
    PS-G202
    PS-G202
    A.4.1Sponsor's protocol code numberPS-G202
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorPARION SCIENCES, INC.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportParion Sciences, Incorporated
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationParion Sciences
    B.5.2Functional name of contact pointClinical Operations
    B.5.3 Address:
    B.5.3.1Street Address2800 Meridian Parkway
    B.5.3.2Town/ cityDurham
    B.5.3.3Post code27713
    B.5.3.4CountryUnited States
    B.5.4Telephone number0019193131202
    B.5.5Fax number0019193131190
    B.5.6E-mailnchurch@parion.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Nebuliser solution
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPInhalation use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNVX-371 / 4,2% NaCl
    D.3.9.2Current sponsor codeVX-371
    D.3.9.4EV Substance CodeSUB181006
    D.3.10 Strength
    D.3.10.1Concentration unit µg/ml microgram(s)/millilitre
    D.3.10.2Concentration typeup to
    D.3.10.3Concentration number30
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Nebuliser solution
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPInhalation use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNVX-371 % 0,17% NaCl
    D.3.9.2Current sponsor codeVX-371
    D.3.9.4EV Substance CodeSUB181006
    D.3.10 Strength
    D.3.10.1Concentration unit µg/ml microgram(s)/millilitre
    D.3.10.2Concentration typeup to
    D.3.10.3Concentration number30
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product name4.2% NaCl
    D.3.4Pharmaceutical form Nebuliser solution
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPInhalation use
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboInhalation vapour, solution
    D.8.4Route of administration of the placeboInhalation use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Primary Ciliary Dyskinesia
    discinesia ciliare primaria
    E.1.1.1Medical condition in easily understood language
    Primary Ciliary Dyskinesia
    discinesia ciliare primaria
    E.1.1.2Therapeutic area Diseases [C] - Respiratory Tract Diseases [C08]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10069713
    E.1.2Term Primary ciliary dyskinesia
    E.1.2System Organ Class 10010331 - Congenital, familial and genetic disorders
    E.1.3Condition being studied is a rare disease Yes
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    Part A:
    To evaluate the safety and efficacy of treatment with VX-371, administered with and without 4.2% hypertonic saline (HS) in subjects with primary ciliary dyskinesia (PCD) who are =12 years of age.

    Parte A:
    Valutare la sicurezza e l¿efficacia del trattamento con VX-371, somministrato con e senza soluzione salina ipertonica (HS) al 4,2% in soggetti affetti da discinesia ciliare primaria (DCP) di et¿ =12 anni.
    E.2.2Secondary objectives of the trial
    Part A:
    To evaluate the effect of VX-371 on quality of life (QOL) in subjects with PCD
    Parte A:
    Valutare l¿effetto di VX-371 sulla qualit¿ di vita (QDV) in soggetti affetti da DCP.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    Subjects who meet all of the following inclusion criteria will be eligible.
    1. Subject (or subject’s legally appointed and authorized representative) will sign and date an informed consent form (ICF) and, where appropriate, assent form.
    2. Willing and able to comply with scheduled visits, treatment plan, study restrictions laboratory tests, contraceptive guidelines, and other study procedures.
    3. Willing and able to use the nebulization device as directed by the instructions for use.
    4. Confirmed diagnosis of PCD based on the following:
    A. Subjects =12 to <18 years of age must meet 2 or more of the following PCD clinical criteria:
    ¿ Unexplained neonatal respiratory distress (at term birth) with need for respiratory support with CPAP and/or oxygen for >24 hours
    ¿ Any organ laterality defect confirmed by chest imaging – situs inversustotalis, situs ambiguous, or heterotaxy
    ¿ Daily, year-round wet or productive cough starting in first year of life or bronchiectasis on chest imaging
    ¿ Daily, year-round nasal congestion starting in first year of life or pansinusitis on sinus imaging
    B. Subjects =18 years of age must have bronchiectasis on chest imaging
    C. All subjects must ALSO have at least one of the following confirmatory tests:
    ¿ For patients with no laterality defect, nNO level during plateau <77 nL/min on 2 occasions, >2 weeks apart, with CF excluded by sweat chloride or genetic testing
    ¿ For patients with a laterality defect, nNO level during plateau <77 nL/min on at least 1 occasion
    ¿ Diagnostic ciliary ultrastructural defect on transmission electron micrograph
    ¿ Two loss of function and/or known mutations in a single PCD-associated gene.
    5. Subjects with percent predicted FEV1 of =40 to <90 percentage points adjusted for age, sex, and height according to the Global Lung Initiative (GLI) at the Screening Visit, taken 4 hours or more after last dose of short-acting bronchodilators (ß-agonists and/or
    anticholinergics)
    6. Non-smoker for the past 90 days prior to the Screening Visit and less than a 5 pack-year lifetime history of smoking, and willing to not smoke while enrolled in the study.
    7. Stable regimen of medications and chest physiotherapy for the 28 days prior to Day 1, and no anticipated need for changes during the study period (other than stopping inhaled HS).
    8. If currently using daily inhaled HS, must be able to discontinue its use for the duration of the study.
    9. If taking daily chronic or chronic cycling antibiotics, has been on a consistent regimen for at least 4 months prior to the Screening Visit. The cycling regimen of antibiotics can be either intermittent monotherapy (e.g., 28 days on/28 days off) or continuous alternating
    therapy (e.g., 28-day cycles of two antibiotics).
    10. Clinically stable (as deemed by the investigator) for at least 14 days prior to the Screening Visit with no evidence of significant new or acute respiratory exacerbations, excluding symptoms of allergic (perennial or seasonal) or non-allergic rhinitis.
    11. Female subjects of childbearing potential must have a negative serum pregnancy test at the Screening Visit. Females of childbearing potential must have a negative urine pregnancy test at the Day 1 and Day 57 visits before receiving the first dose of study drug in each Treatment Period, respectively. Subjects of childbearing potential and who are sexually active must meet the contraception requirements outlined in Section 11.6.5.1.
    Saranno ritenuti idonei i soggetti che soddisfano tutti i criteri di inclusione indicati di seguito.
    1. Il soggetto (o il suo rappresentante nominato e autorizzato ai sensi di legge) deve firmare e datare il modulo di consenso informato (ICF) e, se del caso, il modulo di assenso.
    2. Volontà e capacità di attenersi a visite programmate, piano di trattamento, esami di laboratorio con limitazioni, linee guida sulla contraccezione e altre procedure dello studio.
    3. Volontà e capacità di utilizzare il dispositivo di nebulizzazione come indicato nelle istruzioni per l’uso.
    4. Diagnosi confermata di DCP basata sugli elementi seguenti:1
    A. I soggetti di età compresa tra = 12 e < 18 devono soddisfare almeno due dei seguenti criteri clinici per la DCP:
    ¿ Distress respiratorio neonatale senza causa apparente (parto a termine) con necessità di ventilazione assistita in modalità CPAP e/o ossigeno per > 24 ore
    ¿ Qualsiasi difetto di lateralità d’organo confermato da immagini radiologiche del torace: situs inversus totalis, situs ambiguus o eterotassia
    ¿ Quotidianamente, per tutto l’anno, tosse grassa o produttiva iniziata il primo anno di vita o bronchiectasia nelle immagini radiologiche del torace
    ¿ Quotidianamente, per tutto l’anno, congestione nasale iniziata il primo anno di vita o parasinusite nelle immagini radiologiche dei seni
    B. I soggetti di età = 18 anni devono presentare bronchiectasia nelle immagini radiologiche del torace
    C. Tutti i soggetti devono INOLTRE avere almeno uno dei seguenti esami di conferma:
    ¿ Per i pazienti che non presentano difetti della lateralità, livello nNO durante il plateau < 77 nl/min in 2 occasioni, a distanza di 2 settimane, con esclusione di FC mediante test del sudore o analisi genetica
    ¿ Per i pazienti che presentano difetti della lateralità, livello nNO durante il plateau < 77 nl/min in almeno 1 occasione
    ¿ Diagnosi di difetto ultrastrutturale ciliare alla micrografia elettronica
    ¿ Due perdite di funzione e/o mutazioni note in un gene associato alla DCP.
    5. Soggetti con FEV1 percentuale previsto compreso tra =40 e <90 punti percentuali corretti in base a età, sesso e altezza secondo la Global Lung Initiative (GLI) alla Visita di screening, rilevato almeno 4 ore dopo l’ultima dose di broncodilatatore a breve durata di azione (ß-agonisti e/o anticolinergici)
    6. Non fumatori nei 90 giorni precedenti la Visita di screening e storia di fumo di meno di 5 pacchetti-anno, con volontà di non fumare durante lo studio.
    7. Regime farmacologico stabile e fisioterapia toracica per i 28 giorni precedenti il Giorno 1 e nessuna necessità prevista di modifiche durante il periodo di studio (a esclusione dell’interruzione dell’inalazione di soluzione salina ipertonica).
    8. In caso di attuale utilizzo quotidiano di soluzione salina ipertonica inalata, capacità di interromperne l’uso per la durata dello studio.
    9. In caso di assunzione quotidiana di antibiotici cronici o cronici ciclici, il soggetto deve aver seguito un regime costante per almeno 4 mesi prima della Visita di screening. Il regime ciclico di antibiotici può essere una monoterapia intermittente (ad es. 28 giorni di assunzione/28 giorni di interruzione) o una terapia continua alternata (ad es. cicli di 28 giorni di due antibiotici).
    10. Clinicamente stabile (a parere dello sperimentatore) per almeno 14 giorni prima della Visita di screening senza evidenze di esacerbazioni respiratorie nuove o acute, escludendo sintomi di rinite allergica (perenne o stagionale) o non allergica.
    11. I soggetti di sesso femminile in età fertile devono presentare un test di gravidanza sul siero con esito negativo alla Visita di screening. I soggetti di sesso femminile in età fertile devono presentare un test di gravidanza sulle urine con esito negativo alle visite del Giorno 1 e del Giorno 57 prima di ricevere la dose iniziale di farmaco in studio in ciascun Periodo di trattamento. I soggetti in età fertile sessualmente attivi devono soddisfare i requisiti relativi alla contraccezione esposti nel protocollo completo.
    E.4Principal exclusion criteria
    Subjects who meet any of the following exclusion criteria will not be eligible.
    1. Diagnosis of CF, including at least 1 of the following:
    a. Documented sweat chloride test =60 mM by quantitative pilocarpine iontophoresis or
    b. Abnormal nasal transepithelial potential difference (NPD) test or
    c. 2 CF-causing genetic mutations in the CFTR gene
    2. Subjects with only 1 mutation in the CFTR gene and a sweat chloride test =60 mM by quantitative pilocarpine iontophoresis.
    3. History of any organ transplantation or lung resection or chest wall surgery of such severity that it has an impact on pulmonary function.
    4. Significant congenital heart defects, other than a laterality defect, at the discretion of the investigator.
    5. Diagnosis of Cri du chat syndrome (chromosome 5p deletion syndrome).
    6. Inability to withhold short-acting bronchodilator use for 4 hours prior to clinic visit.
    7. History of any illness or any clinical condition that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug(s) to the subject. This may include, but is not limited to history of clinically significant and uncontrolled adrenal, neurologic, gastrointestinal, renal, hepatic, cardiovascular (including hyper/hypotension and tachy/bradycardia), psychological, pulmonary (other than PCD), metabolic, endocrine, or hematological disorder or disease, or scoliosis of such severity that it impacts pulmonary function or any other major disorder or disease, in the opinion of the investigator.
    8. Used diuretics (including amiloride) or renin-angiotensin antihypertensive drugs (e.g., spironolactone, angiotensin converting enzyme [ACE] and/or neural endopeptidase
    (NEP)-inhibitors, or angiotensin receptor blockers [ARBs]) or trimethoprim or drospirenone in the 28 days before Day 1 or anticipate need for these medications during the study.
    9. Had symptoms of acute upper or lower respiratory tract infection or had an acute pulmonary exacerbation requiring treatment or was treated with systemic antibiotics for ear or sinus disease within 14 days before Day 1 (topical otic antibiotics allowed).
    10. History of significant intolerance to inhaled HS, or intolerance to the single dose of HS at the Screening Visit, as determined by the investigator.
    11. History of drug or alcohol abuse, in the opinion of the investigator.
    12. Known hypersensitivity to the study drug or amiloride.
    13. Pregnant and/or nursing females.
    14. Any clinically significant laboratory abnormalities at the Screening Visit as judged by the investigator, or any of the following:
    a. Plasma or serum potassium > central laboratory vendor upper limit of normal (ULN)
    b. Abnormal renal function, defined as creatinine clearance rate <60 mL/min using the Bedside Schwartz equation (for subjects 12 to17 years of age) or <50 mL/min using the Cockcroft-Gault equation (for subjects =18 years of age).
    c. Abnormal liver function, defined as =3 × ULN for alanine transaminase (ALT), aspartate transaminase (AST), or > 2 x ULN for total bilirubin, unless accounted for by Gilbert’s syndrome (benign indirect hyperbilirubinemia)
    d. Hemoglobin concentration <10.0 g/dL
    15. Unwilling or unable to follow the contraception guidelines as outlined in Section 11.6.5.1.
    16. History of at least two sputum or throat swab cultures yielding B. cepacia complex or M. abscessus or M. avium within the previous 2 years.
    17. Has had surgery within 3 months of Day 1 that required general anesthesia and hospitalization.
    18. Has previously participated in an investigational study involving administration of any investigational compound or use of an investigational device within 28 days prior to the Screening Visit (Note: Participation in a past or concurrent observational study is acceptable).
    19. Has any surgical or medical condition which in the judgment of the investigator might interfere with the absorption, distribution, metabolism, or excretion of the study drug or with safety evaluations.
    20. Is unable to maintain a stable dosage regimen of any concomitant medication throughout the duration of the study.
    Saranno ritenuti non idonei i soggetti che rispondono a uno qualsiasi dei criteri di esclusione indicati di seguito.
    1. Diagnosi di FC con almeno uno degli elementi seguenti:
    a. Esito del test del sudore = 60 mM mediante iontoforesi pilocarpinica quantitativa o
    b. Test della differenza di potenziale nasale (NPD) transepiteliale anomalo o
    c. 2 FC con conseguenti mutazioni genetiche di CFTR
    2. Soggetti che presentano 1 sola mutazione del gene CFTR oltre a un esito del test del sudore = 60 mM mediante iontoforesi pilocarpinica quantitativa.
    3. Anamnesi di trapianto d’organo o resezione polmonare o intervento alla parete toracica di gravità tale da avere ripercussioni sulla funzione polmonare.
    4. Significativi difetti cardiaci congeniti diversi da difetti della lateralità, a discrezione dello sperimentatore.
    5. Diagnosi di sindrome del grido di gatto (sindrome da delezione 5p).
    6. Impossibilità a interrompere l’uso dei broncodilatatori a breve durata d’azione nelle 4 ore precedenti la visita clinica.
    7. Anamnesi di qualsiasi malattia o condizione patologica che, a parere dello sperimentatore, possa confondere i risultati dello studio o rappresentare un ulteriore rischio nella somministrazione del farmaco o dei farmaci in studio al soggetto. Ciò può includere, a titolo non limitativo, anamnesi di patologie o disturbi surrenali, neurologici, gastrointestinali, renali, epatici, cardiovascolari (comprese iper/ipotensione e tachi/bradicardia), psicologici, polmonari (diverse dalla DCP), metabolici, endocrini o ematologici clinicamente significativi e non controllati, o scoliosi di gravità tale da avere ripercussioni sulla funzionalità polmonare o qualsiasi altro disturbo o patologia importante, a parere dello sperimentatore.
    8. Utilizzo di diuretici (inclusa amiloride) o antipertensivi che agiscono sul sistema renina-angiotensina (ad es. spironolattone, inibitori dell’enzima di conversione dell’angiotensina [ACE] e/o dell’endopeptidasi neutra (NEP) o antagonisti del recettore dell’angiotensina [ARB]) oppure trimetropim o drospirenone nei 28 giorni precedenti il Giorno 1 o necessità prevista di questi farmaci durante lo studio.
    9. Insorgenza di sintomi di infezione acuta delle vie aree superiori o inferiori o esacerbazione polmonare acuta con necessità di trattamento o trattata con antibiotici sistemici per patologie dell’orecchio o dei seni nei 14 giorni precedenti il Giorno 1 (consentiti gli antibiotici topici per affezioni auricolari).
    10. Anamnesi di significativa intolleranza alla soluzione salina ipertonica per inalazione o intolleranza alla dose singola di soluzione salina ipertonica alla Visita di screening, secondo quanto determinato dallo sperimentatore.
    11. Storia di abuso di alcol, farmaci o sostanze stupefacenti, a discrezione dello sperimentatore.
    12. Ipersensibilità nota al farmaco in studio o ad amiloride.
    13. Donne in gravidanza e/o in allattamento.
    14. Qualsiasi significativa anomalia degli esami di laboratorio alla Visita di screening secondo il giudizio dello sperimentatore, o una qualsiasi delle evenienze seguenti:
    a. Potassio plasmatico o sierico > limite superiore della norma (ULN) del fornitore del laboratorio centrale
    b. Funzione renale anomala, definita come tasso di clearance della creatinina < 60 ml/min utilizzando l’equazione di Bedside Schwartz (per i soggetti di età compresa tra 12 e 17 anni)2 o < 50 ml/min utilizzando l’equazione di Cockcroft-Gault (per i soggetti di età = 18 anni)3
    c. Funzionalità epatica anomala, definita come = 3 × ULN per alanina aminotransferasi (ALT), aspartato transaminasi (AST) o come > 2 x ULN per bilirubina totale, salvo qualora causate da sindrome di Gilbert (iperbilirubinemia indiretta benigna)
    d. Concentrazione di emoglobina <10,0 g/dl
    15. Assenza della volontà o capacità di seguire le linee guida per la contraccezione indicate nel protocollo completo.
    16. Precedenti esperienze di colture dall’espettorato o tampone faringeo con colture di B. cepacia, M. abscessus o M. avium nei precedenti 2 anni.
    17. Intervento chirurgico nei 3 mesi precedenti il Giorno 1 con necessità di ricovero e anestesia generale.
    18. Precedente partecipazione a uno studio di ricerca con somministrazione di composti sperimentali o uso di dispositivi sperimentali nei 28 giorni precedenti la Visita di screening (N.B.: la partecipazione a uno studio osservazionale concluso o in corso è accettabile).
    19. Condizione chirurgica o medica che a parere dello sperimentatore potrebbe interferire con l’assorbimento, la distribuzione, il metabolismo o l’escrezione del farmaco in studio o con le valutazioni della sicurezza.
    20. Incapacità a seguire un regime di dosaggio stabile di eventuali farmaci concomitanti nel corso dello studio.
    E.5 End points
    E.5.1Primary end point(s)
    Results of safety and tolerability assessments of adverse events (AEs), clinical laboratory values (urine, serum and plasma chemistry, and hematology), 12-lead electrocardiograms (ECGs), spirometry, vital signs, and pulse oximetry.
    I risultati delle valutazioni di sicurezza e tollerabilità degli eventi avversi (EA), valori degli esami clinici di laboratorio (analisi chimica di urine, siero e plasma, ematologia), elettrocardiogramma a 12 canali (ECG), spirometria, segni vitali e pulsiossimetria.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Per TP! sarà valuatato al giorno 28 e per TP2 sarà valutato al giorno 85 --> entrambi comparati al baseline
    For TP1 it will be evaluated at day 28 and for TP2 it will be evaluated at day 85 --> both compared to study baseline
    E.5.2Secondary end point(s)
    Change in QOL score as measured by the PCD Quality of Life Questionnaire (QOL-PCD) and the St. George's Respiratory Questionnaire (SGRQ) after 28 days of treatment
    Variazione del punteggio sulla QDV misurata con i questionari PCD Quality of Life Questionnaire (QOL-PCD) e St. George¿s Respiratory Questionnaire (SGRQ) dopo 28 giorni di trattamento.
    E.5.2.1Timepoint(s) of evaluation of this end point
    For TP1 it will be evaluated at day 28 and for TP2 it will be evaluated at
    day 85 --> both compared to study baseline
    Per TP1 sar¿ valuatato al giorno 28 e per TP2 sar¿ valutato al giorno 85 --> entrambi comparati al baseline
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic Yes
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic Yes
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over Yes
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial4
    E.8.3 The trial involves single site in the Member State concerned Yes
    E.8.4 The trial involves multiple sites in the Member State concerned No
    E.8.4.1Number of sites anticipated in Member State concerned1
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA11
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Belgium
    Canada
    Denmark
    Germany
    Italy
    Netherlands
    Poland
    Sweden
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LVLS
    LVLS
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months1
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months3
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 40
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 100
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 10
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    please, refer to ICF - legal representative
    vedere consenso informato - figura del rappresentante legale
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state18
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 75
    F.4.2.2In the whole clinical trial 150
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    There are no plans for treatment or care following subject completion of participation in the trial.
    Non ci sono piani di trattamento per i soggetti al termine dello studio
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2016-09-26
    N.Ethics Committee Opinion of the trial application
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion
    P. End of Trial
    P.End of Trial StatusCompleted
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 01:39:48 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA